Psoriasis Biologics Face Off in Drug Survival Study  - Takeaways - MDSpire

Psoriasis Biologics Face Off in Drug Survival Study 

Danish registry data reveal differences in treatment persistence

  • By

  • Julie Greenbaum

  • January 14, 2026

  • 2 min

Share

  • 1

    Ustekinumab showed higher drug survival than adalimumab or secukinumab in bionaive psoriasis patients.

  • 2

    In bioexperienced patients, bimekizumab, guselkumab, and risankizumab had the highest 2-year drug survival rates.

  • 3

    The study analyzed data from the DERMBIO registry, covering over 90% of biologic-treated psoriasis patients in Denmark.

  • 4

    At 5 years, the treatment discontinuation risk was lowest for ustekinumab at 37%, compared to 51% for adalimumab.

  • 5

    Bimekizumab had the highest unadjusted 1-year drug survival at 83% among bioexperienced patients.

Original Source(s)

Psoriasis Biologics Face Off in Drug Survival Study 

  • by Julie Greenbaum

  • January 14, 2026

Related Content

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy